Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
NCT06873516Phase 2Completed
- Sponsor
- Evommune
- Start
- Mar 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of EVO756 in chronic spontaneous urticaria (CSU) (4 arms), sponsored by Evommune. Primary endpoint: Urticaria Activity Score at 12 weeks. Started Mar 2025; status: completed.
02
Drugs
EVO756
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06873516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873516.